[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1260502A1 - Vitamin d derivatives having substituents at the 2alpha-position - Google Patents

Vitamin d derivatives having substituents at the 2alpha-position Download PDF

Info

Publication number
EP1260502A1
EP1260502A1 EP01906339A EP01906339A EP1260502A1 EP 1260502 A1 EP1260502 A1 EP 1260502A1 EP 01906339 A EP01906339 A EP 01906339A EP 01906339 A EP01906339 A EP 01906339A EP 1260502 A1 EP1260502 A1 EP 1260502A1
Authority
EP
European Patent Office
Prior art keywords
vitamin
compound
mmol
hydroxy
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01906339A
Other languages
German (de)
French (fr)
Inventor
Hiroaki Takayama
Atsushi Kittaka
Yoshitomo Suhara
Toshie Fujishima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAKAYAMA, HIROAKI
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP1260502A1 publication Critical patent/EP1260502A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Definitions

  • the present invention relates to novel vitamin D derivatives, more particularly, relates to vitamin D derivatives having a substituent at the 2 ⁇ -position.
  • Vitamin D derivatives are known to exhibit a variety of physiological activities such as calcium metabolism regulatory activities, growth-inhibitory and differentiation-inducing activities for tumor cells, and immunoregulatory activities, and various vitamin D derivatives are proposed as therapeutic agents for nephrogenic bone diseases, hypoparathyroidism, osteoporosis and the like.
  • vitamin D derivatives those which have a substituent at the 2 ⁇ -position possess physiological activities such as in vivo calcium metabolism-controlling activity and differentiation-inducing activity on cells such as tumor cells and are reported to be useful as medicines, such as therapeutic agents for diseases associated with abnormal calcium metabolism, for example, osteoporosis and osteomalacia, and antitumor agents (Japanese Patent Publication (Kokoku) No. 6-23185).
  • 2 ⁇ -substituted vitamin D derivatives those having 4-hydroxybutyl or acyloxy at the 2 ⁇ -position were known (J. Org. Chem., Vol.59, No.25, 1994 and Japanese Patent Publication (Kokai) No. 51-19752).
  • the number of reports of 2 ⁇ -substituted vitamin D derivatives is less than that of 2 ⁇ -substituted vitamin D derivatives, and development of 2 ⁇ -substituted vitamin D derivatives having higher physiological activities has been desired.
  • An object of the present invention is to synthesize and provide a novel vitamin D derivative, in which a specific substituent is introduced to the 2 ⁇ -position and the hydroxy at 1- and 3-positions are ⁇ - and ⁇ -oriented, respectively.
  • Another object of the present invention is to provide a novel vitamin D derivative possessing excellent binding property to vitamin D receptor.
  • the inventors of the present invention have found that the binding property to vitamin D receptor is increased by introducing a specific substituent to the 2 ⁇ -position and thereby achieved the present invention.
  • the present invention provides a vitamin D derivative of Formula (1): wherein R 1 and R 2 are straight chained or branched lower alkyl which may be substituted with hydroxy.
  • R 1 is straight chained C 2-6 alkyl substituted with hydroxy and R 2 is straight chained or branched lower C 1-12 alkyl substituted with hydroxy in Formula (1).
  • R 1 is straight chained C 2-4 alkyl substituted with hydroxy and R 2 is straight chained or branched lower C 3-10 alkyl substituted with hydroxy.
  • vitamin D derivative of Formula (2) wherein R 1 is 2-hydroxyethyl or 3-hydroxypropyl and R 3 is 4-hydroxy-4-methylpentyl or 4-ethyl-4-hydroxyhexyl.
  • R 1 is 3-hydroxypropyl and R 3 is 4-hydroxy-4-methylpentyl in Formula (2).
  • vitamin D derivative of the present invention for the manufacture of a medicament for treating diseases accompanied by abnormal calcium metabolism.
  • a method of treating diseases accompanied by abnormal calcium metabolism comprising the step of administering to a host in need of such a treatment a therapeutically effective amount of the vitamin D derivative of the present invention.
  • the vitamin D derivative of the present invention may be useful as a reagent for studying metabolism of active vitamin D 3 (i.e., 1 ⁇ ,25-dihydroxyvitamin D 3 ).
  • R 1 and R 2 represent straight chained or branched lower alkyl which may be substituted with hydroxy.
  • straight chained or branched lower alkyl generally means straight chained or branched C 1-15 alkyl; examples thereof include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl and t-butyl, and also include pentyl, hexyl, heptyl, octyl, nonyl, decanyl, etc.
  • Straight chained or branched lower alkyl which may be substituted with hydroxy means that any hydrogen atom of the above-mentioned lower alkyl may be substituted with one or more hydroxy.
  • the number of hydroxy substituents each of R 1 and R 2 may have is 1, 2 or 3, preferably 1 or 2, and more preferably 1.
  • R 1 is preferably straight chained C 2-6 alkyl substituted with hydroxy and more preferably straight chained C 2-4 alkyl substituted with hydroxy.
  • Non-limiting examples of R 1 include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, etc.
  • R 2 is preferably straight chained or branched lower C 1-12 alkyl substituted with hydroxy and more preferably straight chained or branched lower C 3-10 alkyl substituted with hydroxy.
  • Non-limiting examples of R 2 include 6-hydroxy-6-methyl-2-heptyl, 7-hydroxy-7-methyl-2-octyl, 5,6-dihydroxy-6-methyl-2-heptyl, 4,6,7-trihydroxy-6-methyl-2-heptyl, etc.
  • the vitamin D derivatives of the present invention are preferably compounds of Formula (2).
  • R 1 is 2-hydroxyethyl or 3-hydroxypropyl, more preferably 3-hydroxypropyl in Formula (2).
  • R 3 is 4-hydroxy-4-methylpentyl or 4-ethyl-4-hydroxyhexyl, more preferably 4-hydroxy-4-methylpentyl.
  • the vitamin D derivatives of the present invention can be used as medicaments, for example, as therapeutic agents for diseases accompanied by abnormal calcium metabolism, anti-tumor agents, immunomodulators and the like.
  • vitamin D derivatives of the present invention can be used as reagents for studying the metabolism of active vitamin D 3 (i.e., 1 ⁇ ,25-dihydroxyvitamin D 3 ).
  • the vitamin D derivatives of Formula (1) and Formula (2) of the present invention are novel; although the method of synthesizing them is not limited at all, they may be synthesized, for example, according to the following method.
  • the reference numerals designating compounds in the following synthesis method correspond to those in the reaction schemes of the later-described Examples, this is however, only for the purpose of clearly illustrating and making understandable the following method; the synthesis method of the present invention is not limited to the specific description of the later-described Examples.
  • Crystalline epoxide 1 obtainable from D-glucose and the like, can be used as a starting material. Namely, crystalline epoxide is reacted with an alkanediol, followed by the selective introduction of a functional group to the 3-position to give a 3-substituted derivative 2. Then, after protecting the hydroxy of the functional group at the 3-position to give compound 3 , the benzylideneacetal moiety protecting the hydroxy at the 4- and 6-positions was brominated and cleaved by treatment with brominating reagent such as N-bromosuccinimide and the like, to give bromide 4 .
  • brominating reagent such as N-bromosuccinimide and the like
  • bromide 4 is converted to an alcohol 7 via a diol 5 and a tris-silyl ether 6 .
  • An olefin was formed at 5- and 6-positions of the alcohol by treatment with zinc powder to give a diol 8 .
  • a sulfonate 9 is obtained.
  • ethynyl is introduced to the 1-position to give an enyne 11 .
  • the enyne 11 is treated with potassium carbonate and the like to give an enyne 12 .
  • the hydroxy of the enyne 12 is silylated (e.g.
  • a tris-silyl ether 13 By reacting the tris-silyl ether 13 with a desired bromoolefin 14 (CD-ring part) in an appropriate solvent using a palladium catalyst, a 2 ⁇ -substituted D skeleton is constructed.
  • the thus obtained protected derivative 15 is subjected to deprotection and purified by a usual manner such as reverse phase HPLC and thin layer chromatography to give the desired vitamin D derivative 16 .
  • the protected derivative 15 may be deprotected after purification.
  • CD-ring part compounds of vitamin D derivatives known compounds can be used.
  • a desired CD-ring compound can be obtained by appropriately modifying a side chain of a known CD-ring compound.
  • a CD-ring compound can be obtained from a known vitamin D derivative having a corresponding side chain.
  • Methyl 2,3-anhydro-4,6-O-benzylidene- ⁇ -D-mannopyranoside (Compound 1) (2.52 g, 9.54 mmol), an epoxide, was suspended in 1,3-propanediol (63 mL); potassium tert-butoxide (3.53 g. 31.5 mmol) was added to the suspension, which was heated at 110°C for 14 hours.
  • the reaction mixture was partitioned between methylene chloride (400 mL) and saturated aqueous ammonium chloride (200 mL), and the aqueous layer was extracted with methylene chloride (200 mL) twice.
  • Zinc powder (1.29 g. 19.7 mmol) was further added to the reaction mixture, which was then stirred for 45 min. at the same temperature, cooled and filtered for removing insoluble materials.
  • Sodium borohydride (74.5 mg, 1.97 mmol) was added to the filtrate, which was then stirred for 10 min. at room temperature.
  • Silica gel (1 g) was added, then the mixture was concentrated; the thus obtained concentrated residue was purified by silica gel column chromatography (2% ⁇ 10% ethyl acetate/hexane) to give diol Compound 8 (615.7 mg, yield 72%) as a colorless oil.
  • reaction mixture was partitioned between ethyl acetate (50 mL) and saturated aqueous ammonium chloride (10 mL).
  • the organic layer was washed with saturated aqueous sodium hydrogen carbonate (10 mL), water (10 mL) and saturated brine (10 mL) in that order, dried over anhydrous Na 2 SO 4 and purified by silica gel column chromatography (hexane ⁇ 8% ethyl acetate/hexane) to give olefin Compound 11 (178.0 mg, yield 92%) as a colorless oil.
  • Ethanol solution of 1 ⁇ ,25-dihydroxyvitamin D 3 (the standard substance) and that of the vitamin D derivative of the present invention were prepared at various concentrations.
  • Bovine thymus 1 ⁇ ,25-dihydroxyvitamin D 3 receptor was purchased from Yamasa Biochemcal (Choshi, Chiba, Japan) (lot.110431) and one ampule (approximately 25 mg) of the receptor was dissolved in 55 mL of 0.05 M phosphate 0.5M potassium buffer (pH 7.4) just before use.
  • Each of the ethanol solutions (50 ⁇ l) of vitamin D derivative of the present invention and 1 ⁇ ,25-dihydroxyvitamin D 3 was put into a respective tube with 500 ⁇ l (0.23 mg protein) of the receptor solution, preincubated at room temperature for 1 hour, and [ 3 H]-1 ⁇ ,25-dihydroxyvitamin D 3 was added at the final concentration of 0.1 nM, followed by incubation overnight at 4°C.
  • Each of the reaction mixtures was mixed with DCC (dextran coated charcoal), left for 30 minutes at 4°C and centrifuged at 3000 rpm for ten minutes to separate the bound and free forms of [ 3 H]-1 ⁇ ,25-dihydroxyvitamin D 3 .
  • Each of the resultant supernatants (500 ⁇ l) was mixed with ACS-II (9.5 ml) (AMERSHAM, England) for radioactivity measurement.
  • the binding property of the vitamin D derivative of the present invention was 180 when expressed in relative value with that of 1 ⁇ ,25-dihydroxyvitamin D 3 taken as 100.
  • Vitamin D derivatives represented by Formulae (I) and (II) of the present invention are novel compounds and exhibit excellent physiological activity; they may be useful as medicines for diseases, such as renal bone diseases, hypoparathyroidism, osteoporosis, etc.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

An object of the present invention is to synthesize a novel vitamin D derivative having a substituent at the 2α-position.
According to the present-invention, there is provided a vitamin D derivative of Formula (1):
Figure 80000001
wherein R1 and R2 are straight chained or branched lower alkyl which may be substituted with hydroxy.

Description

    TECHNICAL FIELD
  • The present invention relates to novel vitamin D derivatives, more particularly, relates to vitamin D derivatives having a substituent at the 2α-position.
    • BACKGROUND ART
  • Vitamin D derivatives are known to exhibit a variety of physiological activities such as calcium metabolism regulatory activities, growth-inhibitory and differentiation-inducing activities for tumor cells, and immunoregulatory activities, and various vitamin D derivatives are proposed as therapeutic agents for nephrogenic bone diseases, hypoparathyroidism, osteoporosis and the like.
  • Among numerous vitamin D derivatives, those which have a substituent at the 2β-position possess physiological activities such as in vivo calcium metabolism-controlling activity and differentiation-inducing activity on cells such as tumor cells and are reported to be useful as medicines, such as therapeutic agents for diseases associated with abnormal calcium metabolism, for example, osteoporosis and osteomalacia, and antitumor agents (Japanese Patent Publication (Kokoku) No. 6-23185).
  • As 2α-substituted vitamin D derivatives, those having 4-hydroxybutyl or acyloxy at the 2α-position were known (J. Org. Chem., Vol.59, No.25, 1994 and Japanese Patent Publication (Kokai) No. 51-19752). However, the number of reports of 2α-substituted vitamin D derivatives is less than that of 2β-substituted vitamin D derivatives, and development of 2α-substituted vitamin D derivatives having higher physiological activities has been desired.
  • Thus, paying attention to 2α-substituted vitamin D derivatives, the inventors of the present invention conducted various studies on their physiological activities and other characteristics.
    • DISCLOSURE OF THE INVENTION
  • An object of the present invention is to synthesize and provide a novel vitamin D derivative, in which a specific substituent is introduced to the 2α-position and the hydroxy at 1- and 3-positions are α- and β-oriented, respectively.
  • Another object of the present invention is to provide a novel vitamin D derivative possessing excellent binding property to vitamin D receptor.
  • As a result of careful studies as to achieve the above mentioned objects, the inventors of the present invention have found that the binding property to vitamin D receptor is increased by introducing a specific substituent to the 2α-position and thereby achieved the present invention.
  • Accordingly, the present invention provides a vitamin D derivative of Formula (1):
    Figure 00030001
    wherein R1 and R2 are straight chained or branched lower alkyl which may be substituted with hydroxy.
  • Preferably, R1 is straight chained C2-6 alkyl substituted with hydroxy and R2 is straight chained or branched lower C1-12 alkyl substituted with hydroxy in Formula (1).
  • More preferably, R1 is straight chained C2-4 alkyl substituted with hydroxy and R2 is straight chained or branched lower C3-10 alkyl substituted with hydroxy.
  • According to another aspect of the present invention, there is provided a vitamin D derivative of Formula (2):
    Figure 00030002
    wherein R1 is 2-hydroxyethyl or 3-hydroxypropyl and R3 is 4-hydroxy-4-methylpentyl or 4-ethyl-4-hydroxyhexyl.
  • Preferably, R1 is 3-hydroxypropyl and R3 is 4-hydroxy-4-methylpentyl in Formula (2).
  • According to another aspect of the present invention, there is provided use of the vitamin D derivative of the present invention for the manufacture of a medicament for treating diseases accompanied by abnormal calcium metabolism.
  • According to another aspect of the present invention, there is provided a method of treating diseases accompanied by abnormal calcium metabolism, comprising the step of administering to a host in need of such a treatment a therapeutically effective amount of the vitamin D derivative of the present invention.
  • The vitamin D derivative of the present invention may be useful as a reagent for studying metabolism of active vitamin D3 (i.e., 1α,25-dihydroxyvitamin D3).
  • The whole content of Japanese Patent Application No. 2000-050915, on which the claim for the priority of the present application is based, is incorporated herein by reference.
    • PREFERRED MODE FOR CARRYING OUT THE INVENTION
  • In Formula (1), R1 and R2 represent straight chained or branched lower alkyl which may be substituted with hydroxy.
  • In the present specification, straight chained or branched lower alkyl generally means straight chained or branched C1-15 alkyl; examples thereof include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl and t-butyl, and also include pentyl, hexyl, heptyl, octyl, nonyl, decanyl, etc.
  • Straight chained or branched lower alkyl which may be substituted with hydroxy means that any hydrogen atom of the above-mentioned lower alkyl may be substituted with one or more hydroxy.
  • The number of hydroxy substituents each of R1 and R2 may have is 1, 2 or 3, preferably 1 or 2, and more preferably 1.
  • R1 is preferably straight chained C2-6 alkyl substituted with hydroxy and more preferably straight chained C2-4 alkyl substituted with hydroxy. Non-limiting examples of R1 include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, etc.
  • R2 is preferably straight chained or branched lower C1-12 alkyl substituted with hydroxy and more preferably straight chained or branched lower C3-10 alkyl substituted with hydroxy. Non-limiting examples of R2 include 6-hydroxy-6-methyl-2-heptyl, 7-hydroxy-7-methyl-2-octyl, 5,6-dihydroxy-6-methyl-2-heptyl, 4,6,7-trihydroxy-6-methyl-2-heptyl, etc.
  • The vitamin D derivatives of the present invention are preferably compounds of Formula (2). Preferably, R1 is 2-hydroxyethyl or 3-hydroxypropyl, more preferably 3-hydroxypropyl in Formula (2). Preferably, R3 is 4-hydroxy-4-methylpentyl or 4-ethyl-4-hydroxyhexyl, more preferably 4-hydroxy-4-methylpentyl.
  • Among compounds of Formula (1) of the present invention, (5Z,7E)-(1S,2S,3R,20R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol is preferred.
  • The vitamin D derivatives of the present invention can be used as medicaments, for example, as therapeutic agents for diseases accompanied by abnormal calcium metabolism, anti-tumor agents, immunomodulators and the like.
  • Furthermore, the vitamin D derivatives of the present invention can be used as reagents for studying the metabolism of active vitamin D3 (i.e., 1α,25-dihydroxyvitamin D3).
  • The vitamin D derivatives of Formula (1) and Formula (2) of the present invention are novel; although the method of synthesizing them is not limited at all, they may be synthesized, for example, according to the following method. The reference numerals designating compounds in the following synthesis method correspond to those in the reaction schemes of the later-described Examples, this is however, only for the purpose of clearly illustrating and making understandable the following method; the synthesis method of the present invention is not limited to the specific description of the later-described Examples.
  • Crystalline epoxide 1, obtainable from D-glucose and the like, can be used as a starting material. Namely, crystalline epoxide is reacted with an alkanediol, followed by the selective introduction of a functional group to the 3-position to give a 3-substituted derivative 2. Then, after protecting the hydroxy of the functional group at the 3-position to give compound 3, the benzylideneacetal moiety protecting the hydroxy at the 4- and 6-positions was brominated and cleaved by treatment with brominating reagent such as N-bromosuccinimide and the like, to give bromide 4. The thus obtained bromide 4 is converted to an alcohol 7 via a diol 5 and a tris-silyl ether 6. An olefin was formed at 5- and 6-positions of the alcohol by treatment with zinc powder to give a diol 8. By selective introduction of a leaving group to the primary hydroxy of the diol 8, a sulfonate 9 is obtained. Then, for example, via an epoxide 10, ethynyl is introduced to the 1-position to give an enyne 11. The enyne 11 is treated with potassium carbonate and the like to give an enyne 12. The hydroxy of the enyne 12 is silylated (e.g. tert-butyldimethylsilylated) to give a tris-silyl ether 13. By reacting the tris-silyl ether 13 with a desired bromoolefin 14 (CD-ring part) in an appropriate solvent using a palladium catalyst, a 2α-substituted D skeleton is constructed. The thus obtained protected derivative 15 is subjected to deprotection and purified by a usual manner such as reverse phase HPLC and thin layer chromatography to give the desired vitamin D derivative 16. Alternatively, the protected derivative 15 may be deprotected after purification.
  • As CD-ring part compounds of vitamin D derivatives, known compounds can be used. Alternatively, a desired CD-ring compound can be obtained by appropriately modifying a side chain of a known CD-ring compound. Alternatively, a CD-ring compound can be obtained from a known vitamin D derivative having a corresponding side chain.
    • EXAMPLES
  • The present invention will be described specifically by way of the following Examples, which in no way limit the invention.
  • Reaction schemes carried out in Examples are shown below:
    Figure 00090001
    Figure 00100001
    • (Synthesis Example)
  • Synthesis of (5Z,7E)-(1S,2S,3R,20R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol (Compound 16)
  • In the description of the following Examples, "%" means "volume %" unless otherwise mentioned.
    • (1) Synthesis of methyl-4,6-O-benzylidene-3-O-(3-hydroxypropyl)-α-D-altropyranoside (Compound 2)
  • Methyl 2,3-anhydro-4,6-O-benzylidene-α-D-mannopyranoside (Compound 1) (2.52 g, 9.54 mmol), an epoxide, was suspended in 1,3-propanediol (63 mL); potassium tert-butoxide (3.53 g. 31.5 mmol) was added to the suspension, which was heated at 110°C for 14 hours. The reaction mixture was partitioned between methylene chloride (400 mL) and saturated aqueous ammonium chloride (200 mL), and the aqueous layer was extracted with methylene chloride (200 mL) twice. The combined organic layers were dried over anhydrous sodium sulfate and purified by silica gel column chromatography (10%→66% ethyl acetate/hexane), to give diol Compound 2 (3.06 g, yield 94%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 1.75-1.91(2H,m), 2.42(1H,d.J=5.8Hz), 3.40(3H,s), 3.70-3.81(6H,m), 4.01-4.09(3H,m), 4.29-4.34(2H,m), 4.61(1H,s), 5.56(1H,s), 7.36-7.38(3H,m), 7.47-7.50(2H,m).
    EIMS m/z 340(M+ )
    HREIMS C17H24O7 (M+ ) calcd. 340.1522; found 340.1523
    • (2) Synthesis of methyl 4,6-O-benzylidene-3-O-[3-{(t-butyldimethylsilyl)oxy}propyl]-α-D-altropyranoside (Compound 3)
  • Compound 2 (3.06 g. 8.98 mmol) was dissolved in DMF (30 mL). tert-Butyldimethylsilyl chloride (1.62 g. 10.8 mmol) and imidazole (1.53 g. 22.5 mmol) were added to the resulting solution, which was stirred at room temperature for 3 hours. The reaction mixture was partitioned between ethyl acetate (500 mL) and water (150 mL). The organic layer was washed with water (150 mL) and saturated brine (150 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (10%→33% ethyl acetate/hexane) to give Compound 3 (3.74 g, yield 92%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.02 and 0.03(6H,each s), 0.87(9H,s), 1.78-1.82(2H,m), 1.93(1H,br), 3.39(3H,s), 3.65-3.80(6H,m), 3.95(1H,dd,J=2.7 and 8.8Hz), 3.99-4.00(1H,m), 4.26-4.33(2H,m), 4.89(1H,s), 5.55(1H,s), 7.34-7.37(3H,m), 7.47-7.49(2H,m).
    EIMS m/z 454(M+ ),423(M-OCH3)+, 397(M- tBu)+
    HREIMS C23H38O7Si(M+ ) calcd. 454.2387: found 454.2267
    • (3) Synthesis of methyl 4-O-benzoyl-6-bromo-3-O-[3-{(t-butyldimethylsilyl)oxy}propyl]-6-deoxy-α-D-altropyranoside (Compound 4)
  • Compound 3 (2.42 g. 5.31 mmol) was dissolved in carbon tetrachloride (53 mL). N-bromosuccinimide (1.04 g. 5.84 mmol) and barium carbonate (586.8 mg, 2.97 mmol) were added to the resulting solution, which was heated and refluxed for 40 min. After cooling the reaction mixture, ethyl acetate (50 mL) was added, and insoluble materials were removed through filter paper. The filtrate was partitioned between ethyl acetate (350 mL) and a 0.1N aqueous sodium thiosulfate solution (50 mL). The organic layer was washed with saturated sodium hydrogen carbonate (50 mL), water (50 mL) and saturated brine (50 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (10%→20% ethyl acetate/hexane) to give bromide Compound 4 (2.09 g, yield 74%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ -0.04 and -0.03(6H, each s), 0.83(9H,s), 1.67-1.73(2H,m), 2.52(1H,br s), 3.50(3H,s), 3.55-3.70(6H,m), 3.73(1H,dd,J=4.0 and 7.3Hz), 3.97(1H,dd,J=3.3 and 7.3Hz), 4.35(1H,dt,J=3.7 and 7.0Hz), 4.70(1H,d,J=3.3Hz), 5.45(1H,dd,J=4.0 and 7.0Hz), 7.43-7.47(2H,m), 7.57-7.58(1H,m), 8.03-8.08(2H,m).
    EIMS m/z 519 and 517(M-Me)+, 503 and 501(M-OCH3)+.
    HREIMS C23H37BrO7Si(M+ ) calcd. 532.1492; found 532.1489.
    • (4) Synthesis of methyl 6-bromo-3-O-[3-{(t-butyldimethylsilyl)oxy}propyl]-6-deoxy-α-D-altropyranoside (Compound 5)
  • Compound 4 (2.09 g. 3.92 mmol) was dissolved in CH3OH (50 mL). A 28% NaOCH3 methanol solution (50 mL) was added to the resulting solution, and the reaction was carried out. at room temperature overnight. Silica gel (20 g) was added to the reaction mixture, which was then concentrated under reduced pressure. The thus obtained concentrated residue was purified by silica gel column chromatography (10%→33% ethyl acetate/hexane) to give diol Compound 5 (1.62 g, yield 96%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.06(6H,s), 0.89(9H,s), 1.73-1.85(2H,m), 2.05(1H,brs), 3.00(1H,d,J=8.8Hz), 3.43(3H,s), 3.54(1H,dd,J=7.3 and 10.6Hz), 3.59(1H,t,J=4.6Hz), 3.63(1H,ddd,J=5.5,7.3 and 9.2Hz), 3.69-3.82(5H,m), 3.93-3.98(2H,m), 4.62(1H,d,J=2.2Hz).
    FABMS m/z 469 and 467(M+K)+, 453 and 451(M+Na)+, 431 and 429(M+H)+, 399 and 397(M-OCH3)+, 73 and 371(M- tBu)+
    HREIMS C16H33BrO6Si(M+ ) calcd. 428.1230; found 428.1224.
    • (5) Synthesis of methyl 6-bromo-2,4-bis-(O-t-butyldimethylsilyl)-3-O-[3-{(t-butyldimethylsilyl)oxy}propyl]-6-deoxy-α-D-altropyranoside (Compound 6)
  • Compound 5 (1.84 g. 4.29 mmol) was dissolved in DMF (30 mL). Tert-butyldimethylsilyl chloride (1.94 g. 12.9 mmol) and imidazole (1.17 g. 17.2 mmol) were added to the resulting solution, which was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (450 mL) and water (100 mL). The organic layer was washed with water (100 mL) and saturated brine (100 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (10% ethyl acetate/hexane) to give tris-silyl Compound 6 (2.66 g, yield 94%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.04,0.08,0.09 and 0.11(18H, each s), 0.89 and 0.90(27H, each s), 1.78-1.81(2H,m), 3.37(3H,s), 3.40(1H,m), 3.48(1H,dd,J=7.3 and 10.6Hz), 3.55(1H,dt,J=6.2 and 8.8Hz), 3.64-3.72(4H,m), 3.92-3.96(2H,m), 4.12-4.16(1H,m), 4.48(1H,br s).
    EIMS m/z 658 and 656(M+), 643 and 641(M-Me)+, 601 and 599(M-tBu)+.
    • (6) Synthesis of methyl 6-bromo-4-(O-t-butyldimethylsilyl)-3-O-[3-{(t-butyldimethylsilyl)oxy}propyl]-6-deoxy-α-D-altropyranoside (Compound 7)
  • Compound 6 (2.78 g. 4.23 mmol) was dissolved in THF (25 mL). A 1M solution of tetrabutylammonium fluoride in THF (1.06 mL, 1.06 mmol) was added to the resulting solution, which was stirred at room temperature for 2.5 hours. Silica gel (10 g) was added to the reaction mixture, which was then concentrated under reduced pressure; the thus obtained concentrated residue was purified by silica gel column chromatography (1%→20% ethyl acetate/hexane) to give alcohol Compound 7 (1.16 g, yield 51%), as a colorless oil, and Compound 6 (647.1 mg, yield 23%), which was the starting material of this step.
    1HNMR(400MHz,CDCl3) δ 0.05, 0.11 and 0.12(12H, each s), 0.89 and 0.90(18H, each s), 1.79(2H,ddd,J=2.6,6.2 and 12.8Hz), 2.06(1H,s), 3.42(3H,s), 3.48-3.50(1H,m), 3.52(1H,dd,J=6.2 and 10.8Hz), 3.61-3.68(3H,m), 3.69-3.73(2H,m), 3.93(1H,br), 3.96(1H,dd,J=3.3 and 8.1Hz), 4.11-4.15(1H,m), 4.59(1H,d,J=2.2Hz).
    EIMS m/z 544 and 542(M+), 487 and 485(M-tBu)+
    • (7) Synthesis of (2R,3S,4R)-4-[(t-butyldimethylsilyl)oxy]-3-[3-{(t-butyldimethylsilyl)oxy}propoxy]hex-5-ene-1,2-diol (Compound 8)
  • Compound 7 (1.07 g. 1.97 mmol) was dissolved in 1-propanol (50 mL), and water (5 mL) was added to the solution. Zinc powder (3.86 g. 59.1 mmol) and sodium cyanoborohydride (247.9 mg, 3.94 mmol) were added to the resulting mixture, which was then stirred at 95°C for 20 min. After further addition of zinc power (2.58 g. 39.4 mmol), the reaction was carried out at the same temperature for 35 min., then zinc power (2.58 g. 39.4 mmol) and sodium cyanoborohydride (247.9 mg, 3.94 mmol) were further added, and the reaction was carried out at the same temperature for 30 min. Zinc powder (1.29 g. 19.7 mmol) was further added to the reaction mixture, which was then stirred for 45 min. at the same temperature, cooled and filtered for removing insoluble materials. Sodium borohydride (74.5 mg, 1.97 mmol) was added to the filtrate, which was then stirred for 10 min. at room temperature. Silica gel (1 g) was added, then the mixture was concentrated; the thus obtained concentrated residue was purified by silica gel column chromatography (2%→10% ethyl acetate/hexane) to give diol Compound 8 (615.7 mg, yield 72%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.04, 0.06 and 0.10(12H, each s), 0.89 and 0.90(18H, each s), 1.72-1.80(2H,m), 2.33(1H,t,J=6.0Hz), 3.20(1H,d,J=3.7Hz), 3.22(1H,dd,J=4.4 and 6.6Hz),3.54(1H,m), 3.62-3.75(4H,m), 3.79(1H,m), 3.86(1H,m), 4.36-4.38(1H,m), 5.20(1H,dt,J=1.5 and 10.6Hz), 5.29(1H,dt,J=1.5 and 17.2Hz), 5.89(1H,ddd,J=5.9,10.6 and 17.2Hz).
    EIMS m/z 377(M- tBu)+
    • (8) Synthesis of (2R,3S,4R)-4-[(t-butyldimethylsilyl)oxy]-3-[3-{(t-butyldimethylsilyl)oxy}propoxy]-1-[(2,4,6-trimethylbenzenesulfonyl)oxy]hex-5-en-2-ol (Compound 9)
  • Compound 8 (482.5 mg, 1.11 mmol) was dissolved in CH2Cl2 (11 mL). Under cooling with ice, 2-mesitylenesulfony chloride (267.0 mg, 1.22 mmol) and DMAP (271.2 mg, 2.22 mmol) were added to the resulting solution, which was stirred at 0°C for 1 hour. 2-Mesitylenesulfony chloride (145.6 mg, 0.666 mmol) and DMAP (135.6 mg, 1.11 mmol) were further added to the reaction mixture, which was stirred at 0°C for 3 hours. The reaction mixture was partitioned between ethyl acetate (50 mL) and water (10 mL). The organic layer was washed with water (10 mL) and saturated brine (10 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (10%→17% ethyl acetate/hexane) to give sulfonate Compound 9 (573.1 mg, yield 84%) as a colorless oil.
    1HNMR (400MHz, CDCl3) δ 0.03 and 0.07(12H, each s), 0.87 and 0.88(18H, each s), 1.69-1.76(2H,m), 2.62(9H,s), 3.18 (1H,dd,J=1.8 and 4.8Hz), 3.44(1H,dt,J=6.6 and 8.8Hz), 3.65(2H,t,J=6.0Hz), 3.74(1H,dt,J=6.4 and 9.2Hz), 3.90(1H,dd,J=8.2 and 11.9Hz), 4.01-4.05(2H,m), 4.38(1H,t,J=5.3Hz), 5.20(1H,d,J=10.6Hz), 5.29(1H,d,J=17.2Hz), 5.83(1H,ddd,J=6.0,10.6 and 17.2Hz), 6.96 and 6.98 (2H, each s).
    EIMS m/z 601(M-Me)+, 559(M-tBu)+
    • (9) Synthesis of (3R,4S,5R)-3-[(t-butyldimethylsilyl)oxy]-4-[3-{(t-butyldimethylsilyl)oxy}propoxy]-5,6-epoxyhex-1-ene (Compound 10)
  • Compound 9 (306.7 mg, 0.497 mmol) was dissolved in THF (5 mL). A 1M solution of lithium hexamethyldisilazide in THF (0.596 mL, 0.596 mmol) was added to the resulting solution at -78°C, and then the temperature of the reaction mixture was gradually returned to room temperature. The reaction mixture was partitioned between ethyl acetate (200 mL) and saturated aqueous ammonium chloride (70 mL). The organic layer was washed with water (70 mL) and saturated brine (70 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (hexane→10% ethyl acetate/hexane) to give epoxide Compound 10 (204.7 mg, yield 99%) as a colorless oil.
    1HNMR(400MHz, CDCl3) δ 0.04 and 0.08(12H, each s), 0.88 and 0.90(18H, each s), 1.77(2H, quintet J=6.2Hz), 2.58(1H,dd,J=2.8 and 4.8Hz), 2.76(1H,t,J=4.8Hz), 2.82(1H,t,J=6.2Hz), 3.06(1H,ddd,J=2.8,4.8 and 6.2Hz), 3.55(1H,dt,J=6.2 and 9.5Hz), 3.69(2H,t,J=6.2Hz), 3.76(1H,dt,J=6.2 and 9.5Hz), 4.21(1H,brt,J=6.2Hz), 5.14(1H,d,J=10.3Hz), 5.28(1H,d,J=17.2Hz),
    5.88(1H,ddd,J=6.2,10.3 and 17.2Hz). EIMS m/z 359 (M- tBu)+
    • (10) Synthesis of (4R,5S,6R)-6-[(t-butyldimethylsilyl)oxy]-5-[3-{(t-butyldimethylsilyl)oxy}propoxy]-1-(trimethylsilyl)oct-7-en-1-yn-4-ol (Compound 11)
  • Compound 10 (155.9 mg, 0.374 mmol) was dissolved in THF (5 mL). Meanwhile, trimethylsilylacetylene (0.132 mL, 0.935 mmol) was dissolved in THF (5 mL) and mixed with a butyl lithium hexane solution (1.61M, 0.465 mL, 0.748 mmol) at -78°C and stirred for 5 min. To the solution, the solution of Compound 10 in THF was added at -78°C, boron trifuoride diethy etherate (52.1 µl, 0.411 mmol) was further added, and the reaction temperature was gradually raised to 10°C. The reaction mixture was partitioned between ethyl acetate (50 mL) and saturated aqueous ammonium chloride (10 mL). The organic layer was washed with saturated aqueous sodium hydrogen carbonate (10 mL), water (10 mL) and saturated brine (10 mL) in that order, dried over anhydrous Na2SO4 and purified by silica gel column chromatography (hexane→8% ethyl acetate/hexane) to give olefin Compound 11 (178.0 mg, yield 92%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.04, 0.05, 0.10 and 0.13(15H, each s), 0.89 and 0.91(18H, each s), 1.78-1.81(2H,m), 2.47(1H,dd,J=5.9 and 16.9Hz), 2.53(1H,dd,J=8.4 and 16.9Hz), 3.24(1H,d,J=4.4Hz), 3.31(1H,dd,J=2.2 and 4.4Hz), 3.58(1H,dt,J=6.6 and 9.2Hz), 3.70(2H,t,J=5.9Hz), 3.81(1H,dt,J=6.2 and 9.2Hz), 3.92-3.98(1H,m), 4.42(1H,dd,J=4.4 and 5.9Hz), 5.20(1H,d,J=10.6Hz), 5.31(1H,d,J=17.2Hz), 5.89(1H,ddd,J=5.9,10.6 and 17.2Hz)
    EIMS m/z: 499(M-Me)+, 457(M-tBu)+
    • (11) Synthesis of (4R,5S,6R)-6-[(t-butyldimethylsilyl)oxy]-5-[3-{(t-butyldimethylsilyl)oxy}propoxy]oct-7-en-1-yn-4-ol (Compound 12)
  • Compound 11 (233.6 mg, 0.454 mmol) was dissolved in methanol (10 mL). Potassium carbonate (62.7 mg, 0.454 mmol) was added to the resulting solution, which was stirred at room temperature for 6 hours. After adding acetic acid (52.0 mL, 0.908 mmol), the reaction mixture was concentrated; the residue was partitioned between ethyl acetate (100 mL) and water (30 mL). The organic layer was washed with water (30 mL) and saturated brine (30 mL) in that order, dried over anhydrous sodium sulfate and purified by silica gel column chromatography (hexane→4% ethyl acetate/hexane) to give enyne Compound 12 (193.6 mg, yield 96%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.05, 0.06 and 0.11(12H, each s), 0.89 and 0.91(18H, each s), 1.76-1.83(2H,m), 1.99(1H,t,J=2.7Hz), 2.48(2H,m), 3.27(1H,dd,J=2.2 and 4.4Hz), 3.33(1H,d,J=4.4Hz), 3.58(1H,dt,J=6.6 and 9.2Hz), 3.68-3.73(2H,m), 3.80(1H,dt,J=6.2 and 9.2Hz), 3.96-4.02(1H,m), 4.43(1H,ddt,J=1.5,4.4 and 5.9Hz), 5.22(1H,dt,J=1.5 and 10.6Hz), 5.32(1H,dt,J=1.5 and 17.2Hz), 5.89(1H,ddd,J=5.9,10.6 and 17.2Hz)
    EIMS m/z: 385(M-tBu)+
    • (12) Synthesis of (3R,4S,5R)-3,5-bis-[(t-butyldimethylsilyl)oxy]-4-[3-{(t-butyldimethylsilyl)oxy}propoxy]oct-1-en-7-yne (Compound 13)
  • Compound 12 (193.6 mg, 0.437 mmol) was dissolved in CH2Cl2 (5 mL). Under cooling with ice, tert-butyldimethylsilyltriflate (0.151 mL, 0.656 mmol) and 2,6-lutidine (0.153 mL, 1.31 mmol) were added to the resulting solution, which was stirred at 0°C for 1 hour. The reaction mixture was partitioned between ethyl acetate (150 mL) and saturated aqueous sodium hydrogen carbonate (30 mL). The organic layer was washed with water (30 mL) and saturated brine (30 mL) in that order and purified by silica gel column chromatography (hexane→3% ethyl acetate/hexane) to give tris-silyl Compound 13 (219.3 mg, yield 90%) as a colorless oil.
    1HNMR(400MHz,CDCl3) δ 0.03, 0.05, 0.07, 0.09 and 0.10(18H, each s), 0.89 and 0.90(27H, each s), 1.74-1.80(2H,m), 1.95(1H,t,J=2.6Hz), 2.35(1H,ddd,J=2.6,5.5 and 16.9Hz), 2.49(1H,ddd,2.6,5.5 and 16.9Hz), 3.35(1H,dd,J=3.5 and 5.5Hz), 3.60-3.76(4H,m), 3.88(1H,q,J=5.5Hz), 4.30(1H,dd,J=3.5 and 7.0Hz), 5.12(1H,br d,J=10.3Hz), 5.20(1H,dt,J=1.3 and 17.2Hz), 5.95(1H,ddd,J=7.0,10.3 and 17.2Hz)
    EIMS m/z: 541(M-Me)+, 499(M-tBu)+
    • (13) Synthesis of Compound 16 by the condensation of Compound 13 and Compound 14, followed by deprotection
  • Compound 13 (219.3 mg, 0.394 mmol) and Compound 14 (129.6 mg, 0.363 mmol), which was a vinyl bromide, were dissolved in toluene (5 mL) and mixed with triethylamine (5 mL). Tetrakis(triphenylphosphine)palladium (125.8 mg, 0.109 mmol) was added to the resulting solution, which was then refluxed at 120°C for 90 min. Ethyl acetate (10 mL) was added to the reaction mixture, which was then subjected to a silica gel pad to filter off insoluble materials. The filtrate was concentrated under reduced pressure using a rotary evaporator and roughly purified by silica gel column chromatography (hexane→6% ethyl acetate/hexane) to give 1,3-bis-(O-t-butyldimethylsilyl)-2a-[3-{(t-butyldimethylsilyl)oxy}propoxy]-1α,25-dihydroxyvitamin D3 (Compound 15) as a condensation product.
  • Compound 15 (156.6 mg) was dissolved in THF (3 mL). A solution of tetrabutylammonium fluoride in THF (1M, 0.940 mL, 0.940 mmol) was added to the resulting solution, and reaction was carried out for 96 hours at room temperature. The reaction mixture was concentrated under reduced pressure by a rotary evaporator. The concentrated residue was dissolved in methanol (1 mL) and adsorbed to a silica gel TLC plate (20 × 20 cm, 0.5 mm thick; 10% MeOH in CH2Cl2 ) for purification, giving approximately 75.0 mg of Compound 16 which was a vitamin D derivative. Repeated purification using a silica gel TLC plate gave 56.3 mg of Compound 16 (yield 32%). Purification of Compound 16 using reverse phase HPLC (purification conditions: reverse phase HPLC YMC-Pack ODS column, 20 x 150 mm, 9.0 mL/min, CH3CN:water=3:2) gave white powder.
    Data of Compound 16 purified by reverse phase HPLC 1HNMR(400MHz,CDCl3) δ 0.54(3H,s), 0.93(3H,d,J=6.4Hz), 1.21(6H,s), 2.24(1H,dd,J=9.2 and 13.4Hz), 2.69(1H,dd,J=4.4 and 13.4Hz), 2.81-2.83(1H,m), 3.38(1H,dd,J=3.2 and 7.5Hz),4.03-4.08(1H,m), 4.44(1H,brd,J=2.8Hz), 5.10(1H,d,J=1.8Hz), 5.39(1H,br s), 6.01(1H,d,J=11.3Hz), 6.42(1H,d,J=11.3Hz)
    EIMS m/z: 490(M+), 472(M-H2O)+, 454(M-2H2O)+
    HREIMS C30H50O5 (M+ ) calcd. 490.3660; found 490.3638
    • (Test example) Assay for binding to bovine thymus vitamin D receptor (VDR)
  • Binding property to bovine thymus vitamin D receptor was tested for the vitamin D derivative of the present invention obtained according to the above Synthesis Example.
  • Ethanol solution of 1α,25-dihydroxyvitamin D3 (the standard substance) and that of the vitamin D derivative of the present invention were prepared at various concentrations. Bovine thymus 1α,25-dihydroxyvitamin D3 receptor was purchased from Yamasa Biochemcal (Choshi, Chiba, Japan) (lot.110431) and one ampule (approximately 25 mg) of the receptor was dissolved in 55 mL of 0.05 M phosphate 0.5M potassium buffer (pH 7.4) just before use.
  • Each of the ethanol solutions (50 µl) of vitamin D derivative of the present invention and 1α,25-dihydroxyvitamin D3 was put into a respective tube with 500 µl (0.23 mg protein) of the receptor solution, preincubated at room temperature for 1 hour, and [3H]-1α,25-dihydroxyvitamin D3 was added at the final concentration of 0.1 nM, followed by incubation overnight at 4°C. Each of the reaction mixtures was mixed with DCC (dextran coated charcoal), left for 30 minutes at 4°C and centrifuged at 3000 rpm for ten minutes to separate the bound and free forms of [3H]-1α,25-dihydroxyvitamin D3. Each of the resultant supernatants (500 µl) was mixed with ACS-II (9.5 ml) (AMERSHAM, England) for radioactivity measurement.
  • The binding property of the vitamin D derivative of the present invention was 180 when expressed in relative value with that of 1α,25-dihydroxyvitamin D3 taken as 100. The value was calculated according to the following equation: X=(y/x) × 100
  • X: relative VDR binding property of the vitamin D derivative of the present invention
  • y: concentration of 1α,25-dihydroxyvitamin D3 that inhibits 50% of the binding of [3H]1α,25-dihydroxyvitamin D3 and VDR
  • x: concentration of the vitamin D derivative of the present invention that inhibits 50% of the binding of [3H]1α,25-dihydroxyvitamin D3 and VDR
    • INDUSTRIAL APPLICABILITY
  • Vitamin D derivatives represented by Formulae (I) and (II) of the present invention are novel compounds and exhibit excellent physiological activity; they may be useful as medicines for diseases, such as renal bone diseases, hypoparathyroidism, osteoporosis, etc.

Claims (5)

  1. A vitamin D derivative of Formula (1):
    Figure 00250001
    wherein
    R1 and R2 are straight chained or branched lower alkyl which may be substituted with hydroxy.
  2. The vitamin D derivative of claim 1, wherein R1 is straight chained C2-6 alkyl substituted with hydroxy and R2 is straight chained or branched C1-12 alkyl substituted with hydroxy.
  3. The vitamin D derivative of claim 1, wherein R1 is straight chained C2-4 alkyl substituted with hydroxy and R2 is straight chained or branched C3-10 alkyl substituted with hydroxy.
  4. A vitamin D derivative of Formula (2):
    Figure 00260001
    wherein
    R1 is 2-hydroxyethyl or 3-hydroxypropyl and R3 is 4-hydroxy-4-methylpentyl or 4-ethyl-4-hydroxyhexyl.
  5. The vitamin D derivative of claim 4, wherein R1 is 3-hydroxypropyl and R3 is 4-hydroxy-4-methylpentyl.
EP01906339A 2000-02-28 2001-02-27 Vitamin d derivatives having substituents at the 2alpha-position Withdrawn EP1260502A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000050915 2000-02-28
JP2000050915 2000-02-28
PCT/JP2001/001451 WO2001062723A1 (en) 2000-02-28 2001-02-27 VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2α-POSITION

Publications (1)

Publication Number Publication Date
EP1260502A1 true EP1260502A1 (en) 2002-11-27

Family

ID=18572644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01906339A Withdrawn EP1260502A1 (en) 2000-02-28 2001-02-27 Vitamin d derivatives having substituents at the 2alpha-position

Country Status (6)

Country Link
US (1) US20030022872A1 (en)
EP (1) EP1260502A1 (en)
KR (1) KR20020092955A (en)
CN (1) CN1398254A (en)
AU (1) AU2001234189A1 (en)
WO (1) WO2001062723A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2634171A1 (en) * 2010-10-25 2013-09-04 Teijin Pharma Limited 23-yne-vitamin d3 derivative

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011241170A (en) * 2010-05-18 2011-12-01 Mercian Corp Vitamin d derivative and method for producing the same
WO2013162047A1 (en) * 2012-04-24 2013-10-31 帝人ファーマ株式会社 Therapeutic agent for secondary hyperparathyroidism
AU2020276888B2 (en) * 2019-05-13 2023-02-16 Faes Farma, S.A. Process and intermediates for the preparation of eldecalcitol
CN114685553B (en) * 2020-12-29 2024-01-30 南京圣鼎医药科技有限公司 Preparation method of idecalcitol intermediate and intermediate thereof
CN115057804B (en) * 2022-05-27 2024-03-29 南京海融制药有限公司 Calcitriol purification method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780773B2 (en) * 1986-06-05 1995-08-30 中外製薬株式会社 New Vitamin D (3) A drug containing a derivative as an active ingredient
ATE210642T1 (en) * 1995-01-23 2001-12-15 Chugai Pharmaceutical Co Ltd 2-SUBSTITUTED VITAMIN D3 DERIVATIVES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0162723A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2634171A1 (en) * 2010-10-25 2013-09-04 Teijin Pharma Limited 23-yne-vitamin d3 derivative
EP2634171A4 (en) * 2010-10-25 2013-11-13 Teijin Pharma Ltd 23-yne-vitamin d3 derivative
US9006220B2 (en) 2010-10-25 2015-04-14 Teijin Pharma Limited 23-yne-vitamin D3 derivative
US9079843B2 (en) 2010-10-25 2015-07-14 Teijin Pharma Limited 23-yne-vitamin D3 derivative
RU2558362C2 (en) * 2010-10-25 2015-08-10 Тейдзин Фарма Лимитед 23-in-vitamin d3 derivative

Also Published As

Publication number Publication date
WO2001062723A1 (en) 2001-08-30
CN1398254A (en) 2003-02-19
US20030022872A1 (en) 2003-01-30
AU2001234189A1 (en) 2001-09-03
KR20020092955A (en) 2002-12-12

Similar Documents

Publication Publication Date Title
US4554105A (en) Process for the preparation of 1-hydroxylated vitamin D compounds
MX2010014023A (en) Crystal of spiroketal derivative, and process for production thereof.
US20030022872A1 (en) Vitamin d derivatives having substituents at the 2 alpha-position
US5604257A (en) Lactone compound and process of production thereof
DK145083B (en) PROSTAGLANDIN ANALOGUE FOR USE IN AGENTS FOR REGULATING THE REPRODUCTIVE CYCLOS OF HEALTHY MAMMALS
CN102796134B (en) Preparation method for Maxacalcitol intermediate
JPH06298783A (en) New process for producing glycoside
IE55921B1 (en) 5-halovinyl-2'-deoxyuridine derivatives
LU83992A1 (en) NEW FLUORPROSTACYCLINE
CN101679469A (en) Widow-the β of modification-(1,3)-dextran is used for the treatment of purposes, the widow-β-(1 of disease of immune system, 3)-dextran-(1,3)-seminose, widow-β-(1,3)-dextran-(1,3)-N.F,USP MANNITOL and their derivative, their preparation method and the medicine that contains them
WO2002066424A1 (en) Vitamin d derivative having substituent in 2-position
JPH05117230A (en) Prostaglandin derivative
WO1998050353A1 (en) Vitamin d3 derivatives and process for producing the same
CA2190560A1 (en) Process for producing vitamin d3 derivatives
CN102351860A (en) Synthesis method of panipenem and intermediates thereof
US20050113349A1 (en) 2-Alpha vitamin D derivatives having substituents
US20060074255A1 (en) 3-Methyl-20-epi-vitamin D derivatives
US4603208A (en) Certain polyprenyl intermediates
JP3595025B2 (en) Vitamin D3 derivative and method for producing the same
JPH08325226A (en) Production of vitamin d3 derivative
JP2006083091A (en) Method for producing trehalose type disaccharide and its derivative and new trehalose type disaccharide derivative
JPH0219839B2 (en)
JPH0321034B2 (en)
JPH09316093A (en) Polyphosphoric acid derivative
JPH11116551A (en) Vitamin d3 derivative and its production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKAYAMA, HIROAKI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049149

Country of ref document: HK